Today, October 26, 2020, Emotra AB (“Emotra” or “the Company”) published the results of the TO 2020 series subscription-warrant conversion. 201026 - Emotra - PM - Result subscription warrants of TO 2020 series
News archive
CEO Daniel Poté intends to exercise his subscription warrants
Daniel Poté, Emotra AB’s CEO (“Emotra” or “the Company”) has notified that he intends to exercise his right to convert 50% of his subscription warrants in connection with the second phase of Emotra’s rights issue. 201016 - Emotra - PM - CEO Daniel Poté intends...
Emotra enters an agreement to develop the German market
Emotra has just entered an agreement with Mediq Innovation Experts GmbH (“Mediq”) concerning a future establishment on the German market. 201009 - Emotra - PM - Emotra enters agreement to develop the german market
Claes Holmberg, the chairman of the board, intends to convert his subscription warrants
Claes Holmberg, the chairman of the board of Emotra AB (“Emotra” or “the Company”) has notified that he intends to exercise his right to convert subscription warrants..... 201008 - Emotra - PM - Chairman Claes Holmberg intends to convert subscription...
Emotra postpones the publication of its third-quarter report
Emotra AB (“Emotra” or “the Company”) has decided to postpone the publication of its third-quarter report. 201007 - Emotra - PM - Emotra, postpones publication of 3q report
Emotra announces the exercise price for subscription warrants in the TO 2020 rights issue
On October 6, 2020, Emotra AB (“Emotra” or “the Company”) established the exerciseprice for subscription warrants in the TO 2020 rights issue (“the Subscription warrants”). 201007 - Emotra - PM - Emotra, exercise price for subscription warrants in to...
Update on our research on depression relapse
Our efforts to plan and recruit clinics for our study to document the connection between hyporeactivity and depression relapse continues. 200929 - Emotra - PM - Emotra, update on research
EMOTRA AB: Presentation at Aktiespararna’s Shareholder day
Emotra will be holding a presentation at Aktiespararna’s Shareholder day. To watch the whole presentation, please click the link below: 2000908 - Emotra- PM - Presentation at Aktiespararna's shareholder day
Emotra AB (publ) Interim report January 1 – June 30, 2020
The Board and CEO of Emotra AB (publ) hereby present the interim report for the first six months of 2020. 200825 Interim report Jan- June 2020
Emotra has signed a collaboration agreement for clinical studies with the General Psychiatry clinic at Örebro University hospital
Emotra has lately been focusing on the indication area depression relapse. Our goal is to start a clinical study in 2020. Emotra’s agreement with the General Psychiatry clinic (Allmänpsykiatriska kliniken) at Örebro University Hospital is another important step...